nach oben

Erschienen in:

28.09.2023 | Research

Treatment outcomes for response-based radiotherapy in children and adolescents with central nervous system germinoma: a prospective study

verfasst von: Chenggong Zeng, Qunying Yang, Zhuoran Li, Zhiqing Wei, Tingting Chen, Meiling Deng, Jian Wang, Juan Wang, Feifei Sun, Junting Huang, Suying Lu, Jia Zhu, Xiaofei Sun, Zijun Zhen

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The optimal dose and range of radiotherapy for central nervous system (CNS) germinoma have not yet been established. This study aimed to investigate the effects of individualized radiotherapy on the prognosis of patients with germinoma.

Methods

Based on imaging examination, tumor markers, and pathologic results, patients with germinoma received different radiotherapy strategies, including R1 (24 Gy whole ventricular irradiation + tumor-bed boost to 40 Gy), R2 (24–30 Gy craniospinal irradiation + tumor-bed boost to 54 Gy), R3 (24 Gy craniospinal irradiation + tumor-bed boost to 40 Gy), and R4 (30 Gy craniospinal irradiation + tumor-bed boost to 54 Gy with 45 Gy to spinal metastasis).

Results

A total of 77 patients were enrolled in this study between January 2015 and March 2021. The 3-year event-free survival (EFS) and overall survival (OS) of the whole cohort were 94.7% ± 2.6% and 96.0% ± 2.3%, respectively. The 3-year EFS for patients with localized and metastatic disease were 96.6% ± 2.4% and 89.2% ± 7.2%, respectively. The 3-year EFS of patients receiving R1, R2, R3, and R4 radiotherapy were 100%, 94.1% ± 5.7%, 100%, and 86.2% ± 9.1%, respectively.

Conclusion

Good prognosis was still achieved after reducing dose and extent of radiation for the patients who achieved complete response (CR) after induction chemotherapy or pathological CR after second-look surgery.

Nur mit Berechtigung zugänglich

Thakkar JP, Chew L, Villano JL (2013) Primary CNS germ cell tumors: current epidemiology and update on treatment. Med Oncol 30:496. https://doi.org/10.1007/s12032-013-0496-9CrossRefPubMed

Echevarria ME, Fangusaro J, Goldman S (2008) Pediatric central nervous system germ cell tumors: a review. Oncologist 13:690–699. https://doi.org/10.1634/theoncologist.2008-0037CrossRefPubMed

Lee SH, Jung KW, Ha J, Oh CM, Kim H, Park HJ, Yoo H, Won YJ (2017) Nationwide Population-Based incidence and Survival Rates of Malignant Central Nervous System Germ Cell Tumors in Korea, 2005–2012. Cancer Res Treat 49:494–501. https://doi.org/10.4143/crt.2016.129CrossRefPubMed

Horbinski C, Berger T, Packer RJ, Wen PY (2022) Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours. Nat Rev Neurol 18:515–529. https://doi.org/10.1038/s41582-022-00679-wCrossRefPubMed

Calaminus G, Kortmann R, Worch J, Nicholson JC, Alapetite C, Garre ML, Patte C, Ricardi U, Saran F, Frappaz D (2013) SIOP CNS GCT 96: final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease. Neuro Oncol 15:788–796. https://doi.org/10.1093/neuonc/not019CrossRefPubMedPubMedCentral

Cheng S, Kilday JP, Laperriere N, Janzen L, Drake J, Bouffet E, Bartels U (2016) Outcomes of children with central nervous system germinoma treated with multi-agent chemotherapy followed by reduced radiation. J Neurooncol 127:173–180. https://doi.org/10.1007/s11060-015-2029-1CrossRefPubMed

Bartels U, Onar-Thomas A, Patel SK, Shaw D, Fangusaro J, Dhall G, Souweidane M, Bhatia A, Embry L, Trask CL, Murphy ES, MacDonald S, Wu S, Boyett JM, Leary S, Fouladi M, Gajjar A, Khatua S (2022) Phase II trial of response-based radiation therapy for patients with localized germinoma: a Children’s Oncology Group study. Neuro Oncol 24:974–983. https://doi.org/10.1093/neuonc/noab270CrossRefPubMed

Jain R, Robertson PL, Gandhi D, Gujar SK, Muraszko KM, Gebarski S (2005) Radiation-induced cavernomas of the brain. AJNR Am J Neuroradiol 26:1158–1162PubMedPubMedCentral

Murray MJ, Bartels U, Nishikawa R, Fangusaro J, Matsutani M, Nicholson JC (2015) Consensus on the management of intracranial germ-cell tumours. Lancet Oncol 16:e470–e477. https://doi.org/10.1016/S1470-2045(15)00244-2CrossRefPubMed

10.

Nakamura H, Takami H, Yanagisawa T, Kumabe T, Fujimaki T, Arakawa Y, Karasawa K, Terashima K, Yokoo H, Fukuoka K, Sonoda Y, Sakurada K, Mineharu Y, Soejima T, Fujii M, Shinojima N, Hara J, Yamasaki K, Fujimura J, Yamasaki F, Takahashi M, Suzuki T, Sato I, Nishikawa R, Sugiyama K (2022) The Japan Society for Neuro-Oncology guideline on the diagnosis and treatment of central nervous system germ cell tumors. Neuro Oncol 24:503–515. https://doi.org/10.1093/neuonc/noab242CrossRefPubMed

11.

Wang L, Yamaguchi S, Burstein MD, Terashima K, Chang K, Ng HK, Nakamura H, He Z, Doddapaneni H, Lewis L, Wang M, Suzuki T, Nishikawa R, Natsume A, Terasaka S, Dauser R, Whitehead W, Adekunle A, Sun J, Qiao Y, Marth G, Muzny DM, Gibbs RA, Leal SM, Wheeler DA, Lau CC (2014) Novel somatic and germline mutations in intracranial germ cell tumours. Nature 511:241–245. https://doi.org/10.1038/nature13296CrossRefPubMedPubMedCentral

12.

Takami H, Perry A, Graffeo CS, Giannini C, Narita Y, Nakazato Y, Saito N, Nishikawa R, Matsutani M, Ichimura K, Daniels DJ (2020) Comparison on epidemiology, tumor location, histology, and prognosis of intracranial germ cell tumors between Mayo Clinic and japanese consortium cohorts. J Neurosurg 134:446–456. https://doi.org/10.3171/2019.11.JNS191576CrossRefPubMed

13.

14.

Rogers SJ, Mosleh-Shirazi MA, Saran FH (2005) Radiotherapy of localised intracranial germinoma: time to sever historical ties? Lancet Oncol 6:509–519. https://doi.org/10.1016/S1470-2045(05)70245-XCrossRefPubMed

15.

da Silva NS, Cappellano AM, Diez B, Cavalheiro S, Gardner S, Wisoff J, Kellie S, Parker R, Garvin J, Finlay J (2010) Primary chemotherapy for intracranial germ cell tumors: results of the third international CNS germ cell tumor study. Pediatr Blood Cancer 54:377–383. https://doi.org/10.1002/pbc.22381CrossRefPubMed

16.

Kellie SJ, Boyce H, Dunkel IJ, Diez B, Rosenblum M, Brualdi L, Finlay JL (2004) Intensive cisplatin and cyclophosphamide-based chemotherapy without radiotherapy for intracranial germinomas: failure of a primary chemotherapy approach. Pediatr Blood Cancer 43:126–133. https://doi.org/10.1002/pbc.20026CrossRefPubMed

17.

Sun XF, Zhang F, Zhen ZJ, Yang QY, Xia YF, Wu SX, Zhu J, Lu SY, Wang J, Sun FF, Cai RQ, Chen Y, Li PF (2014) The clinical characteristics and treatment outcome of 57 children and adolescents with primary central nervous system germ cell tumors. Chin J Cancer 33:395–401. https://doi.org/10.5732/cjc.013.10112CrossRefPubMedPubMedCentral

18.

Calaminus G, Frappaz D, Kortmann RD, Krefeld B, Saran F, Pietsch T, Vasiljevic A, Garre ML, Ricardi U, Mann JR, Gobel U, Alapetite C, Murray MJ, Nicholson JC (2017) Outcome of patients with intracranial non-germinomatous germ cell tumors-lessons from the SIOP-CNS-GCT-96 trial. Neuro Oncol 19:1661–1672. https://doi.org/10.1093/neuonc/nox122CrossRefPubMedPubMedCentral

19.

Oya S, Saito A, Okano A, Arai E, Yanai K, Matsui T (2014) The pathogenesis of intracranial growing teratoma syndrome: proliferation of tumor cells or formation of multiple expanding cysts? Two case reports and review of the literature. Childs Nerv Syst 30:1455–1461. https://doi.org/10.1007/s00381-014-2396-5CrossRefPubMed

20.

Kong DS, Nam DH, Lee JI, Park K, Kim JH, Shin HJ (2009) Intracranial growing teratoma syndrome mimicking tumor relapse: a diagnostic dilemma. J Neurosurg Pediatr 3:392–396. https://doi.org/10.3171/2009.1.PEDS0857CrossRefPubMed

21.

Frappaz D, Dhall G, Murray MJ, Goldman S, Faure Conter C, Allen J, Kortmann RD, Haas-Kogen D, Morana G, Finlay J, Nicholson JC, Bartels U, Souweidane M, Schonberger S, Vasiljevic A, Robertson P, Albanese A, Alapetite C, Czech T, Lau CC, Wen P, Schiff D, Shaw D, Calaminus G, Bouffet E (2022) EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults. Neuro Oncol 24:516–527. https://doi.org/10.1093/neuonc/noab252CrossRefPubMed

22.

Afzal S, Wherrett D, Bartels U, Tabori U, Huang A, Stephens D, Bouffet E (2010) Challenges in management of patients with intracranial germ cell tumor and diabetes insipidus treated with cisplatin and/or ifosfamide based chemotherapy. J Neurooncol 97:393–399. https://doi.org/10.1007/s11060-009-0033-zCrossRefPubMed

23.

Alapetite C, Brisse H, Patte C, Raquin MA, Gaboriaud G, Carrie C, Habrand JL, Thiesse P, Cuilliere JC, Bernier V, Ben-Hassel M, Frappaz D, Baranzelli MC, Bouffet E (2010) Pattern of relapse and outcome of non-metastatic germinoma patients treated with chemotherapy and limited field radiation: the SFOP experience. Neurooncology 12:1318–1325. https://doi.org/10.1093/neuonc/noq093CrossRef

24.

Ogawa K, Yoshii Y, Shikama N, Nakamura K, Uno T, Onishi H, Itami J, Shioyama Y, Iraha S, Hyodo A, Toita T, Kakinohana Y, Tamaki W, Ito H, Murayama S (2008) Spinal recurrence from intracranial germinoma: risk factors and treatment outcome for spinal recurrence. Int J Radiat Oncol Biol Phys 72:1347–1354. https://doi.org/10.1016/j.ijrobp.2008.03.055CrossRefPubMed

Titel: Treatment outcomes for response-based radiotherapy in children and adolescents with central nervous system germinoma: a prospective study
verfasst von: Chenggong Zeng
Qunying Yang
Zhuoran Li
Zhiqing Wei
Tingting Chen
Meiling Deng
Jian Wang
Juan Wang
Feifei Sun
Junting Huang
Suying Lu
Jia Zhu
Xiaofei Sun
Zijun Zhen
Publikationsdatum: 28.09.2023
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2023
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-023-04453-w

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2023

The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial

Impact of timing of antiseizure medication withdrawal on seizure recurrence in glioma patients: a retrospective observational study

RAI-measured frailty predicts non-home discharge following metastatic brain tumor resection: national inpatient sample analysis of 20,185 patients

Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses

Supramaximal resection based on en-bloc technique reduces tumor burden and prolongs survival in primary supratentorial lobar glioblastoma